Literature DB >> 24967467

[Caution with hypofractionated dose-escalating radiotherapy in non-small cell lung cancer].

Julia Philipp, Michael Baumann.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24967467     DOI： 10.1007/s00066-014-0667-4

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  8 in total

1.  Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC).

Authors:  M Baumann; T Herrmann; R Koch; W Matthiessen; S Appold; B Wahlers; L Kepka; G Marschke; D Feltl; R Fietkau; V Budach; J Dunst; R Dziadziuszko; M Krause; D Zips
Journal:  Radiother Oncol       Date:  2011-07-13       Impact factor: 6.280

2.  Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee.

Authors:  M Saunders; S Dische; A Barrett; A Harvey; G Griffiths; M Palmar
Journal:  Radiother Oncol       Date:  1999-08       Impact factor: 6.280

3.  Short communication: adverse chronic effects of high-dose irradiation on proximal bronchus in patients treated for bronchogenic carcinoma.

Authors:  K Hayakawa; N Mitsuhashi; Y Saito; N Nakajima; H Niibe
Journal:  Br J Radiol       Date:  1993-05       Impact factor: 3.039

4.  Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy.

Authors:  Jose S A Belderbos; Wilma D Heemsbergen; Katrien De Jaeger; Paul Baas; Joos V Lebesque
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-09-01       Impact factor: 7.038

5.  Dose, volume, and tumor control prediction in primary radiotherapy of non-small-cell lung cancer.

Authors:  Jochen Willner; Kurt Baier; Ekaterini Caragiani; Axel Tschammler; Michael Flentje
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-02-01       Impact factor: 7.038

6.  Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis.

Authors:  Audrey Mauguen; Cécile Le Péchoux; Michele I Saunders; Steven E Schild; Andrew T Turrisi; Michael Baumann; William T Sause; David Ball; Chandra P Belani; James A Bonner; Aleksander Zajusz; Suzanne E Dahlberg; Matthew Nankivell; Sumithra J Mandrekar; Rebecca Paulus; Katarzyna Behrendt; Rainer Koch; James F Bishop; Stanley Dische; Rodrigo Arriagada; Dirk De Ruysscher; Jean-Pierre Pignon
Journal:  J Clin Oncol       Date:  2012-07-02       Impact factor: 44.544

7.  Improved local control with higher doses of radiation in large-volume stage III non-small-cell lung cancer.

Authors:  Ramesh Rengan; Kenneth E Rosenzweig; Ennapadam Venkatraman; Lawrence A Koutcher; Jana L Fox; Reena Nayak; Howard Amols; Ellen Yorke; Andrew Jackson; C Clifton Ling; Steven A Leibel
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-11-01       Impact factor: 7.038

8.  Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer.

Authors:  Donald M Cannon; Minesh P Mehta; Jarrod B Adkison; Deepak Khuntia; Anne M Traynor; Wolfgang A Tomé; Richard J Chappell; Ranjini Tolakanahalli; Pranshu Mohindra; Søren M Bentzen; George M Cannon
Journal:  J Clin Oncol       Date:  2013-10-21       Impact factor: 44.544
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.